immune checkpoint inhibition
Results Trial description recap V1

Atezolizumab - Avelumab - Durvalumab - Durvalumab + tremelimumab - Ipilimumab - Nivolumab - Pembrolizumab

Advanced breast cancer (metastatic)

all type of patients 1 trials

Gastric or gastro-oesophageal junction cancer (advanced)

all type of patients 3 trials

Head and neck cancer

all type of patients 2 trials

Lung cancer (metastatic)

all type of patients 23 trials

first line 1 trials

first line 11 trials

second line 7 trials

Melanoma

all type of patients 17 trials

first line 7 trials

second line (or later) 6 trials

adjuvant setting 3 trials

Multiple myeloma

all type of patients 2 trials

Renal-cell carcinoma (advanced)

all type of patients 2 trials

Urothelial carcinoma (advanced)

all type of patients 8 trials